Automeris.oi, Extract data from charts (2024)

Beloqui A et al (2014) pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int J Pharm 473(1–2):203–212

Article  CAS  PubMed  Google Scholar 

Berre CL, HS, Peyrin-Biroulet L (2023) Ulcerative colitis. Lancet 402. https://doi.org/10.1016/S0140-6736(23)00966-2

Courthion H, MT, Rousseaux C, Möller M, Gurny R, Gabriel D, Self-assembling polymeric nanocarriers to target inflammatory lesions in ulcerative colitis. J Control Release, 2017. https://doi.org/10.1016/j.jconrel.2017.07.044

Cui M, FZ, Song M, Zhou T, Wang Y, Liu K (2022) Phragmites rhizoma polysaccharide-based nanocarriers for synergistic treatment of ulcerative colitis. Int J Biol Macromol 220. https://doi.org/10.1016/j.ijbiomac.2022.07.245. https://doi.org/10.1016/j.ijbiomac.2022.07.245

Guada M, BA, Alhouayek M, Muccioli G.G, Dios-Viéitez M.D.C, Préat V, Blanco-Prieto MJ (2016) Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease treatment. Int J Pharm. https://doi.org/10.1016/j.ijpharm.2016.03.012

Gut IiESIJ, Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case–control study within a European prospective cohort study. 2009. 58(12): 1606–1611. https://doi.org/10.1136/gut.2008.169078

Hooijmans, CR, Rovers MM, de Vries RB et al (2014) SYRCLE’s risk of bias tool for animal studies. . BMC Med Res Methodol 14. https://doi.org/10.1186/1471-2288-14-43

Jones GR, LM, Plevris N (2019) IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gutt. https://doi.org/10.1136/gutjnl-2019-318936

Kazemifard N, Golestani N, Jahankhani K, Farmani, M, Ghavami SB (2024) Ulcerative colitis: the healing power of macrophages. Tissue Barriers. https://doi.org/10.1080/21688370.2024.2390218

Kobayashi T, Siegmund B, Le Berre C et al (2020) Ulcerative colitis. Nat Rev Dis Primers 6. https://doi.org/10.1038/s41572-020-0205-x

Lee J, SA, Hlaing SP, Kwak D, Kim H, Kim J, Lee E.H,Yoo J-W (2022) Cupriavidus necator-produced polyhydroxybutyrate/Eudragit FS hybrid nanoparticles mitigates ulcerative colitis via colon-targeted delivery of cyclosporine A. Pharmaceutics 14. https://doi.org/10.3390/pharmaceutics14122811

Naeem M, LJ, Oshi MA, Cao J, Hlaing SP, Im E, Jung Y, Yoo JW (2020) Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2020.09.017

Naeem M, BJ, Oshi MA, Kim MS, Moon HR, Lee BL, Im E, Jung Y, Yoo JW (2018) Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. Int J Nanomedicine. https://doi.org/10.2147/IJN.S157566

Oshi MA, JL, Kim J, Hasan N, Im E, Jung Y, Yoo J-W (2021) pH-Responsive alginate-based microparticles for colon-targeted delivery of pure cyclosporine A crystals to treat ulcerative colitis. Pharmaceutics 13:9. https://doi.org/10.3390/pharmaceutics13091412

Page MJ, MJE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https://doi.org/10.1136/bmj.n71

Porter RJ, Kalla R, Ho GT (2020) Ulcerative colitis: recent advances in the understanding of disease pathogenesis. F1000Res. https://doi.org/10.12688/f1000research.20805.1

Sung J, AZ, Long D, Yang C, Merlin D (2022) Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: a novel therapeutic solution to treat ulcerative colitis. Biomaterials 288. https://doi.org/10.1016/j.biomaterials.2022.121707

Wu Y, MS, Wang D, Li G, Huang J, Tan S, Bao L, Li Q, Li G, Si L (2019) Pep T1 medicinal nano system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis. Biomater Sci. https://doi.org/10.1039/C9BM00925F

Xiong M, LY, He H, Hao S, Fang P, Xu M, Chen Y,Chen Y, Yu S,Hu H (2023) Cyclosporine A-loaded colon-targeted oral nanomicelles self-assembly by galactosylated carboxymethyl chitosan for efficient ulcerative colitis therapy. Eur J Pharm Biopharm 189. https://doi.org/10.1016/j.ejpb.2023.06.010

Zhang M, Merlin D (2018) Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis. Inflamm Bowel Dis 24:1401

Article  PubMed  PubMed Central  Google Scholar